Workflow
美容和保健服务
icon
Search documents
美丽田园医疗健康(02373):25年业绩高增,内生增长+外延并购双驱动
GF SECURITIES· 2026-03-31 02:46
Investment Rating - The report assigns a "Buy" rating to the company, with a current price of HKD 19.30 and a fair value of HKD 30.13 [5]. Core Insights - The company has achieved significant growth in 2025, with a revenue of RMB 3.001 billion, representing a year-on-year increase of 16.65%. The net profit reached RMB 340 million, up 34.77%, and the attributable net profit was RMB 318 million, reflecting a 39.00% increase. The adjusted net profit was RMB 381 million, showing a growth of 40.97% [8]. - The strong performance is attributed to accelerated external expansion, including the acquisition of the Nair brand, which enhances market share, and sustained organic growth driven by high-margin business segments [8]. - The company operates three main business segments: beauty and health services, medical beauty services, and sub-health medical services, all of which have shown growth in revenue and profitability [8]. Financial Summary - Revenue projections for 2024 to 2028 are as follows: RMB 2.572 billion (2024), RMB 3.001 billion (2025), RMB 4.013 billion (2026), RMB 4.786 billion (2027), and RMB 5.644 billion (2028), with growth rates of 19.9%, 16.7%, 33.7%, 19.3%, and 17.9% respectively [4][12]. - The company's EBITDA is projected to grow from RMB 704 million in 2024 to RMB 1.311 billion in 2028, with a notable increase in net profit from RMB 228 million in 2024 to RMB 651 million in 2028 [4][12]. - The report highlights a significant improvement in profitability metrics, with ROE expected to rise from 24.2% in 2024 to 35.8% in 2028 [4][12]. Business Performance - The beauty and health services segment generated RMB 1.658 billion in 2025, up 14.88%, while medical beauty services and sub-health medical services achieved revenues of RMB 1.017 billion and RMB 326 million, respectively, with growth rates of 9.56% and 62.16% [8]. - The gross margins for these segments were reported at 41.88%, 55.87%, and 64.31%, respectively, indicating an upward trend in profitability [8]. Strategic Outlook - The company is positioned as a leader in the industry, with a strong brand portfolio including Meili Tianyuan, Nair, and Siyuanli, which collectively enhance its competitive advantage [8]. - The dual strategy of organic growth and external acquisitions is expected to drive sustained high growth in the coming years, supported by refined operational efficiencies and scale effects [8].
美丽田园医疗健康(02373):业绩高增,内生外延双轮驱动
Investment Rating - The report maintains a "Buy" rating for the company, indicating a potential upside of over 15% relative to the benchmark index [5][6]. Core Insights - The company achieved a revenue of 3.001 billion RMB in 2025, representing a year-over-year growth of 16.65%, with an adjusted net profit of 381 million RMB, up 40.96% year-over-year [2]. - The company's growth is driven by both organic and external factors, with three main business segments contributing to revenue: beauty and wellness services, medical beauty services, and sub-health medical services [3][5]. - The gross margin for 2025 was 49.05%, an increase of 2.79 percentage points year-over-year, driven by cost optimization and a shift towards higher-margin consumer medical services [4]. Revenue Breakdown - Beauty and wellness services generated 1.658 billion RMB, up 14.88% year-over-year, with direct store sales contributing 1.512 billion RMB, reflecting a 15.82% increase due to increased customer traffic and active membership [3]. - Medical beauty services accounted for 1.017 billion RMB, growing 9.56% year-over-year, supported by the "Double Beauty + Double Wellness" business model [3]. - Sub-health medical services saw significant growth of 62.16%, reaching 326 million RMB, attributed to an expanding membership base and a diversified product service matrix [3]. Financial Metrics - The adjusted net profit margin for 2025 was 12.69%, an increase of 2.19 percentage points year-over-year, reflecting improved operational efficiency [4]. - The company plans to continue its growth strategy through a combination of internal development and acquisitions, with expected revenues of 4.008 billion RMB in 2026, representing a 33.6% increase [5][6]. Future Projections - Revenue forecasts for 2026-2028 are 4.008 billion RMB, 4.519 billion RMB, and 4.897 billion RMB, with respective growth rates of 33.6%, 12.8%, and 8.4% [6]. - Adjusted net profits are projected to be 500 million RMB, 600 million RMB, and 693 million RMB for the same period, with growth rates of 31.2%, 20.1%, and 15.5% [6].
【美丽田园医疗健康(2373.HK)】业绩表现靓丽,三大业务板块协同向上 ——2025年报点评(姜浩/吴子倩)
光大证券研究· 2026-03-29 00:04
Core Viewpoint - The company reported a revenue of 3 billion yuan in 2025, representing a year-on-year growth of 16.7%, and a net profit attributable to shareholders of 320 million yuan, up 39.0% [4] Group 1: Financial Performance - In 2025, the company achieved an operating cash flow of 1 billion yuan, an increase of 25.4% year-on-year [4] - The first half of 2025 generated revenues of 1.46 billion yuan, a 28.2% increase, while the second half saw revenues of 1.54 billion yuan, a 7.5% increase [4] - The adjusted net profit for 2025 was 380 million yuan, reflecting a year-on-year growth of 41.0% [4] Group 2: Business Segments Performance - The beauty and health services segment generated 1.66 billion yuan, up 14.9%, while medical beauty services and sub-health medical services achieved revenues of 1.02 billion yuan and 330 million yuan, growing by 9.6% and 62.2% respectively [5] - In the first half of 2025, beauty and health services revenue was 810 million yuan, a 29.6% increase, while the second half saw a revenue of 850 million yuan, a 3.7% increase [5] - The medical beauty services segment had a customer flow of 102,000, a 13.1% increase, and an average annual spending of 28,000 yuan per active member, up 490 yuan [6] Group 3: Growth Strategies - The company is focusing on a "super brand + super chain + super digitalization" strategy to enhance its long-term development [9] - The company has made strategic acquisitions of the second-largest brand, Nairui'er, and the third-largest brand, Siyuanli, to strengthen its market position [9] - The company aims to leverage high-margin medical services and rapidly growing sub-health services to create synergistic effects within its business model [9] Group 4: Operational Metrics - The company had a total of 550 stores by the end of 2025, with a slight decrease of 4 stores year-on-year [7] - The number of direct-operated stores in beauty and health services increased by 13 to 252, while franchise stores decreased by 16 to 260 [7] - The gross profit margin improved by 2.8 percentage points to 49.1%, and the net profit margin increased by 1.7 percentage points to 10.6% [8]
美丽田园医疗健康附属拟4000万元收购奈瑞儿相关医疗及美容资产 新增19家直营门店
Zhi Tong Cai Jing· 2025-11-18 11:51
Core Viewpoint - Meili Tianyuan Medical Health (02373) announced a share transfer agreement to acquire 100% equity of medical businesses in Dongguan and Zhuhai for a total consideration of RMB 40 million (approximately HKD 44 million) [1] Group 1: Acquisition Details - The buyer, a non-wholly owned subsidiary of the company, will acquire 90% equity of the target company upon completion of the acquisition [1] - The acquisition will lead to the addition of 19 new direct-operated stores, including 2 medical beauty stores and 17 lifestyle beauty stores, expanding the company's direct store scale [1] - The acquisition is expected to enhance the company's revenue significantly and deepen its market penetration in core cities of the Greater Bay Area [1] Group 2: Target Business Operations - The medical targets in Dongguan and Zhuhai are operated by Guangzhou Nairui Health Medical Investment Co., Ltd., focusing on medical outpatient services [1] - The Zhuhai target, Zhuhai Nairui Naimei Beauty Technology Co., Ltd., operates 8 Nairui brand beauty and health service stores [1] - The Dongguan target, Nairui Beauty Chain (Dongguan) Co., Ltd., operates 9 Nairui brand beauty and health service stores [1]
国证国际:维持美丽田园医疗健康(02373)“买入”评级 目标价45港元
Zhi Tong Cai Jing· 2025-09-19 01:46
Group 1 - The core viewpoint of the report is that Meili Tianyuan Medical Health (02373) is expected to maintain strong financial performance, with projected revenues of 3.05 billion, 3.41 billion, and 3.76 billion RMB for 2025-2027, and net profits of 320 million, 380 million, and 440 million RMB respectively [1] - The company achieved record high adjusted net profit in H1 2025, with revenues, net profit, and adjusted net profit reaching 1.46 billion, 170 million, and 190 million RMB respectively, representing year-on-year growth of 28%, 36%, and 38% [1] - The operating cash flow for H1 2025 was 410 million RMB, an increase of 84% year-on-year, with cash and cash equivalents amounting to 2 billion RMB, up 28% [1] Group 2 - The beauty and health services segment generated 810 million RMB in revenue, a year-on-year increase of 30%, while the medical beauty services segment achieved 500 million RMB, growing by 13% [1] - The sub-health medical services segment saw a remarkable revenue increase of 108%, reaching 150 million RMB, with the number of outpatient clinics expanding to 11 [1] - The Women's Health Center, a key part of the sub-health medical business, reported a revenue growth of 173% in H1 2025 [1] Group 3 - The company increased its stake in Nairu to 90%, enhancing profitability, with Nairu's revenue reaching 280 million RMB in H1 2025 and adjusted net profit margin rising from 6.5% to 10.4% [2] - Nairu, recognized as the "First Brand of Intelligent Beauty and Health" by Frost & Sullivan, is implementing an AI-driven transformation project called "Intelligent Beauty and Health 2.0 System" [2] Group 4 - The company has announced a "Capital Market Value Enhancement Plan" aimed at increasing shareholder returns, optimizing capital structure, and promoting sustainable development, with a total of 300 million RMB in dividends declared over the past three years [3] - The first dividend payment from the shareholder return plan is scheduled to be distributed by September 26, 2025, at a rate of 0.52 HKD per share [3]
美丽田园医疗健康(02373.HK):业绩高增 “内生+外延”战略持续显效
Ge Long Hui· 2025-09-04 04:09
Core Insights - The company reported a revenue of 1.46 billion yuan for the first half of 2025, representing a year-on-year increase of 28.2%, and a net profit of 170 million yuan, up 35.5% year-on-year [1] - The company's three main business segments showed strong growth, with the sub-health medical service revenue doubling [1] Revenue Breakdown - Beauty and health services generated 810 million yuan, a year-on-year increase of 29.6%, accounting for 55.2% of total revenue, driven by improved same-store sales and the acquisition of the smart beauty brand Nairui [1] - Medical beauty services achieved 500 million yuan in revenue, up 13.0% year-on-year, representing 34.2% of total revenue, supported by the execution of the "internal growth + external acquisition" strategy [1] - Sub-health medical services reached 150 million yuan, a significant increase of 107.8% year-on-year, making up 10.6% of total revenue, attributed to the strategy attracting members and refined operations [1] Profitability Metrics - The gross margin for the first half of 2025 was 49.3%, an increase of 2.3 percentage points year-on-year [2] - The net profit margin stood at 11.70%, reflecting a year-on-year increase of 0.62 percentage points [2] - The company maintained a stable expense ratio, with sales, management, and R&D expense ratios at 17.19%, 16.22%, and 1.44%, respectively [2] Strategic Initiatives - The company emphasized its "internal growth + external acquisition" strategy, with the acquisition of Nairui, the second-largest brand in China's beauty industry, expected to be completed by July 2024 [2] - Nairui contributed 277 million yuan in revenue during the first half of 2025, with an adjusted net profit margin increasing from 6.5% to 10.4% post-acquisition [2] - The company plans to enhance Nairui's core advantages and implement its first AI digital transformation project, the "Smart Beauty 2.0 System" [2] Membership Growth - The company reported a 47.8% year-on-year increase in customer traffic to 920,000 visits at direct stores, and active membership grew by 46.5% to 120,000 [3] - Approximately 20% of beauty and health service members upgraded to medical beauty or sub-health services, driving higher-value business penetration [3] Investment Outlook - The company is expected to achieve net profits of 330 million yuan, 380 million yuan, and 430 million yuan for 2025-2027, representing year-on-year growth of 43.9%, 17.0%, and 12.2% respectively [3] - The current stock price corresponds to a price-to-earnings ratio of 23X, 20X, and 18X for 2025-2027 [3]
美丽田园医疗健康(02373):业绩高增,“内生+外延”战略持续显效
Minsheng Securities· 2025-09-02 05:32
Investment Rating - The report maintains a "Buy" rating for the company, indicating a potential upside of over 15% relative to the benchmark index [4]. Core Insights - The company achieved significant growth in the first half of 2025, with revenue reaching 1.46 billion RMB, a year-on-year increase of 28.2%, and net profit of 170 million RMB, up 35.5% [1]. - The "internal growth + external acquisition" strategy has proven effective, particularly with the acquisition of the brand Nairui, which contributed 277 million RMB in revenue and improved its net profit margin from 6.5% to 10.4% [3]. - The company reported a gross margin of 49.3%, an increase of 2.3 percentage points year-on-year, and a net profit margin of 11.70%, up 0.62 percentage points [3]. Revenue Breakdown - The revenue from beauty and wellness services was 810 million RMB, a 29.6% increase, accounting for 55.2% of total revenue. Direct store income was 740 million RMB, up 31.0% [2]. - Medical beauty services generated 500 million RMB, a 13.0% increase, representing 34.2% of total revenue [2]. - The revenue from sub-health medical services doubled to 150 million RMB, a 107.8% increase, making up 10.6% of total revenue [2]. Membership Growth - The company reported a 47.8% increase in direct store customer traffic, reaching 920,000 visits, and active membership grew by 46.5% to 120,000 [4]. - Approximately 20% of beauty and wellness service members upgraded to medical beauty or sub-health services, enhancing the penetration of high-value business [4]. Financial Forecast - The company is projected to achieve net profits of 330 million RMB, 380 million RMB, and 430 million RMB for 2025, 2026, and 2027, respectively, with growth rates of 43.9%, 17.0%, and 12.2% [4][5]. - The current stock price corresponds to a price-to-earnings ratio (P/E) of 23X for 2025, 20X for 2026, and 18X for 2027 [4][5].
美丽田园医疗健康(02373.HK):1H经调净利同增38% 外延整合提效顺利推进
Ge Long Hui· 2025-08-30 04:01
Core Viewpoint - The company reported strong performance in 1H25, exceeding previous forecasts and expectations, driven by scale effects and operational efficiency improvements [1][2]. Financial Performance - Revenue for 1H25 reached 1.46 billion yuan, a year-on-year increase of 28.2% - Net profit attributable to shareholders was 160 million yuan, up 34.9% - Adjusted net profit was 190 million yuan, reflecting a 37.8% increase [1] - Gross margin improved by 2.4 percentage points to 49.3%, attributed to scale effects reducing procurement costs and diluting fixed costs [2] - Adjusted net profit margin reached a historical high of 13.1%, up 0.9 percentage points year-on-year [2] Business Segments - Beauty and health services generated 810 million yuan in revenue, a 29.6% increase, with direct store traffic up 48.6% to 850,000 visits [1] - Medical beauty services revenue was 500 million yuan, a 13.0% increase, with active membership rising 27.6% to 24,000 [1] - Sub-health medical services saw revenue growth of 107.8% to 150 million yuan, with active members increasing 93.4% to 7,014 [1] Growth Strategy - The company is expanding its store network, adding 69 direct/franchise beauty and health service stores, 3 medical beauty stores, and 2 sub-health stores in 1H25 [1] - The company is focusing on enhancing operational efficiency and exploring acquisition opportunities to increase market share [3] - Recent changes in shareholder structure, including the entry of quality medical capital, are expected to support long-term growth [3] Valuation and Outlook - The company maintains its profit forecasts for 2025-2026, with current stock price corresponding to 25/21x P/E for those years [3] - Target price has been raised by 8% to 40 HKD, indicating a 21% upside potential based on the company's strong business model and growth opportunities [3]
中金:维持美丽田园医疗健康跑赢行业评级 上调目标价至40港元
Zhi Tong Cai Jing· 2025-08-28 03:28
Core Viewpoint - The company maintains its profit forecast for 2025-2026, with a target price increase of 8% to HKD 40, indicating a 21% upside potential based on its strong business model and growth opportunities [1] Financial Performance - The company reported 1H25 revenue of RMB 1.46 billion, a year-on-year increase of 28.2%, and a net profit attributable to shareholders of RMB 160 million, up 34.9% [2] - Adjusted net profit reached RMB 190 million, reflecting a 37.8% year-on-year growth, exceeding previous forecasts due to scale effects and operational efficiency improvements [2] Business Segments - Beauty and wellness services generated RMB 810 million in revenue, a 29.6% increase, with direct store traffic rising 48.6% to 850,000 visits [3] - Medical beauty services achieved RMB 500 million in revenue, up 13.0%, with active membership increasing 27.6% to 24,000 [3] - Sub-health medical services saw a remarkable revenue growth of 107.8% to RMB 150 million, with active members increasing 93.4% to 7,014 [3] Margin and Efficiency - The company's gross margin improved by 2.4 percentage points to 49.3% in 1H25, driven by scale effects and the inclusion of higher-margin businesses [4] - The adjusted net profit margin reached a historical high of 13.1%, with a year-on-year increase of 0.9 percentage points [4] Growth Strategy - The company is focused on enhancing operational efficiency and increasing service penetration through digital marketing [4] - It is also exploring acquisition opportunities to boost market share, with recent shareholder structure optimization expected to support long-term growth [4]
中金:维持美丽田园医疗健康(02373)跑赢行业评级 上调目标价至40港元
智通财经网· 2025-08-28 03:17
Core Viewpoint - Company maintains profit forecasts for 2025-2026, with a target price increase of 8% to HKD 40, indicating a 21% upside potential based on strong business model advantages and growth opportunities [1] Financial Performance - Company reported 1H25 revenue of RMB 1.46 billion, a year-on-year increase of 28.2%; net profit attributable to shareholders reached RMB 160 million, up 34.9%; adjusted net profit was RMB 190 million, reflecting a 37.8% increase, exceeding previous forecasts and expectations due to scale effects and operational efficiency [2] Business Segments - Beauty and wellness services generated RMB 810 million in revenue, a 29.6% increase, with direct store traffic up 48.6% to 850,000 and active membership rising 45.7% to 112,000; medical beauty services revenue was RMB 500 million, up 13.0%, with active members increasing 27.6% to 24,000; sub-health medical services revenue surged 107.8% to RMB 150 million, now accounting for over 10% of total revenue, with active members growing 93.4% to 7,014 [3] - The company expanded its store network, adding 69 direct/franchise beauty and wellness stores to reach 238/276, 3 medical beauty stores to total 27, and 2 sub-health stores to 11 [3] Profitability and Efficiency - Gross margin improved by 2.4 percentage points year-on-year to 49.3%, driven by scale effects that reduced procurement costs and diluted fixed costs; adjusted net profit margin reached a historical high of 13.1%, up 0.9 percentage points year-on-year [4] Growth Outlook - The company is focused on enhancing single-store operational efficiency and increasing value-added service penetration while exploring acquisition opportunities to boost market share; recent shareholder structure optimization is expected to support long-term quality growth [5]